Loading news...
Citigroup Inc. purchased a new position in shares of Claritev (NYSE: CTEV) during the undefined quarter, according to its most recent 13F filing with the SEC. The firm purchased 38,146 shares of the company's stock, valued at approximately $2,025,000. Citigroup Inc. owned about 0.23% of Claritev at the end of the most recent
Claritev Corporation (CTEV) Discusses Business Outlook and Addresses Investor Questions Following Recent Quarter Transcript
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced that members of its management team will meet with investors at the following investor events in March 2026: Mizuho Virtual Healthcare Technology Conference 2026 – Thursday, March 5, 2026 - 1x1 meetings hosted virtually Q&A Webcast Hosted by Nephron Research – Friday,.
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, will host its 2026 Investor Day on Monday, March 16, 2026 at the New York Stock Exchange. The event will feature presentations by members of Claritev's management team discussing the company's long term growth strategy, vertical markets, product roadmap, and financial outlook, along with.
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Claritev Corporation (NYSE: CTEV). The investigation focuses on Claritev's executive officers and whether investor losses may be recovered under federal securities laws.
Claritev Corporation (CTEV) Q4 2025 Earnings Call Prepared Remarks Transcript
Claritev Corporation (CTEV) came out with a quarterly loss of $4.88 per share versus the Zacks Consensus Estimate of a loss of $3.96. This compares to a loss of $5.14 per share a year ago.
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the fourth quarter and full year ended December 31, 2025. “I am exceedingly proud of the work delivered by the Claritev team in 2025. This year marked a pivotal time in our company's history, as we returned to top line revenue growth highlighted by op.
Shares of Claritev (NYSE: CTEV - Get Free Report) fell 0.8% during mid-day trading on Thursday. The stock traded as low as $22.90 and last traded at $23.38. 92,225 shares were traded during trading, a decline of 33% from the average session volume of 137,849 shares. The stock had previously closed at $23.56. Analysts Set
MCLEAN, Va--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, announced today that it will release its fourth quarter and fiscal year 2025 financial results after market close on Monday, February 23, 2026, and hold a conference call at 4:30 pm Eastern Time. To join the conference call, please pre-register using the link below. Participant.
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent, and fair for all, today announced a strategic relationship with Kinetiq Health, a healthcare risk management organization specializing in claims surveillance, diagnostic certainty, and cost intervention strategies. Rising medical and pharmacy costs are often driven by a small number of complex, high-cost.
Claritev Corporation (CTEV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Management will be presenting on Thursday, January 15, 2026 at 7:30 a.m. PT. A live webcast and audio archive of the presentation will be available through the investor relations section of Claritev's.
Claritev Corporation (CTEV) Presents at Bank of America Leveraged Finance Conference Transcript
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation Announces Participation at Upcoming Conferences.
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced the pricing of an underwritten public offering (the “Offering”) of 1,500,000 shares of its Class A common stock, par value $0.0001 per share (the “Class A common stock”), by certain affiliates of Hellman & Friedman (collectively, the “Selling Stockholders”) at a price.
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced the commencement of an underwritten public offering (the “Offering”) of 1,500,000 shares of its Class A common stock, par value $0.0001 per share (the “Class A common stock”), by certain affiliates of Hellman & Friedman (collectively, the “Selling Stockholders”). The.
Claritev Corporation ( CTEV ) Q3 2025 Earnings Call November 7, 2025 8:00 AM EST Company Participants Todd Friedman - Vice President of Investor Relations Travis Dalton - CEO, President & Chairman Doug Garis - Executive VP & CFO Conference Call Participants Joshua Raskin - Nephron Research LLC Daniel Grosslight - Citigroup Inc. Exchange Research Jessica Tassan - Piper Sandler & Co., Research Division Presentation Operator Hello, everyone, and thank you for joining us today for the Claritev Corporation Third Quarter Earnings Call. My name is Sami, and I'll be coordinating your call today.
Claritev Corporation (CTEV) came out with a quarterly loss of $4.07 per share versus the Zacks Consensus Estimate of a loss of $3.12. This compares to a loss of $1.85 per share a year ago.
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation Reports Third Quarter 2025 Results.